Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Concert licenses deuterium-modified narcolepsy program to Jazz

Executive Summary

Concert Pharmaceuticals Inc. (chemically modified versions of existing small molecules) has licensed oncology and CNS company Jazz Pharmaceuticals PLC exclusive global rights to its deuterium-containing sodium oxybate analog (D-SXB) program. The deal includes lead preclinical candidate C10323, which could be ready for IND filing in late 2013.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Contract
    • Includes Royalty or Profit Split Information

Related Companies

UsernamePublicRestriction

Register